



The Cardiac Society of Australia and New Zealand

## Position Statement Atrial Fibrillation Ablation

**This position statement was developed by A/Prof Andrew McGavigan and members of the EP and Pacing Council Executive.**

**The statement was reviewed by the Continuing Education and Recertification Committee and ratified at the CSANZ Board meeting held on Friday, 31<sup>st</sup> May 2013.**

The Cardiac Society of Australia and New Zealand supports catheter ablation in selected patients as a Class 1 indication for paroxysmal atrial fibrillation and a Class 2A indication for more persistent forms. This is in accordance with most recent European and American guidelines<sup>1,2</sup>, and is supported in the Australasian environment by two recent papers endorsed by the CSANZ<sup>3,4</sup>. Currently there is significant inequity of access to these procedures and the CSANZ supports calls to redress this imbalance to ensure all patients have access to best practice.

1. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow Up, Definitions, Endpoints, And Research Trial Design. Calkins H et al. *Europace* 2012; 14: 528-606.
2. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Updating the 2006 Guideline). Wann L et al. *J Am CollCardiol* 2011; 57: 223-242.
3. National Heart Foundation of Australia Consensus Statement on Catheter Ablation as a Therapy for Atrial Fibrillation. Kalman J et al. *Med J Australia* 2013; 198: 518-521.
4. Catheter Ablation for Atrial Fibrillation. Thomas S et al. *Heart, Lung, Circ* 2012; 21: 395-401.